Studienname/Acronym

Studientitel

Prüfarzt/Fachgebiet

Link zur Studie (Register)

CIFFREO (C3391003)

A Phase 3, Multicenter, Randomizes, Double-blind, Placebo-controlled Study to evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Andrea Klein / Neuropädiatrie

clinicaltrials.gov/study/NCT04281485

VX22-121-106

A Phase 3, Open-label Study Evaluating the Long‑term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older

Philipp Latzin / Pneumologie

clinicaltrials.gov/study/NCT05844449

BEAR

A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho-Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years with Wheezing Lower Respiratory Illness

Philipp Latzin / Pneumologie

clinicaltrials.gov/study/NCT05677763

BOCAB

Bern Obesity in Childhood and Adolescence Biorepository

Christoph Saner / Endokrinologie

--

ELIPSE I

Early Life Intervention in Pediatrics Supported by E-health (ELIPSE I): coaching parents to lower obesity in children A single-blind randomized controlled parallel-group clinical trial

Matthias Kopp / Endokrinologie

clinicaltrials.gov/study/NCT06208345

AbbVie M16-194

A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease

Christiane Sokollik / Gastrologie

clinicaltrials.gov/study/NCT05995353

VX22-445-122

A Phase 3, Open-label Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 to Less Than 24 Months of Age

Philipp Latzin / Pneumologie

clinicaltrials.gov/study/NCT05882357

VX22-445-123

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 Months of Age and Older

Philipp Latzin / Pneumologie

clinicaltrials.gov/study/NCT06460506

The Mythic Study

A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia

Philipp Agyeman / Infektiologie

clinicaltrials.gov/study/NCT06325293

Vedolizumab SC-3003

An Open-label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Who Achieved Clinical Response Following Open-label Vedolizumab Intravenous Therapy

Christiane Sokollik / Gastrologie

clinicaltrials.gov/study/NCT06100289

ProKind

ProKind - Project on classification monitoring and therapy in pediatric rheumatology

Klaus Tenbrock

--

ELIPSE II

Early Life Intervention in Pediatrics Supported by E-health (ELIPSE II): coaching parents to lower second-hand smoke exposure in children A single-blind randomized controlled parallel-group clinical trial

Matthias Kopp

clinicaltrials.gov/study/NCT06311162

DIAMONDS

Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis.

Philipp Agyeman / Infektiologie

--

CAR-CF

COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF Investigator Initiated Trial of the European Cystic Fibrosis Clinical Trial Network (ECFS-CTN

Philipp Latzin / Pneumologie

clinicaltrials.gov/study/NCT05074680

Swiss-CP-Reg

Swiss Cerebral Palsy Registry

Sebastian Grunt / Neuropädiatrie

www.swiss-cp-reg.ch